Kedrion Biopharma participated in the 2023 International Plasma Protein Congress (IPPC), held in Lisbon, Portugal, on June 20-21, organized by the Plasma Protein Therapeutics Association (PPTA). The theme chosen by PPTA for this edition is “From Donor to Patient“.
The Congress brought together policymakers, stakeholders, patient groups and industry in Europe to discuss the need to increase plasma collection, regulatory and policy developments, patient health and donor safety.
On the first day of IPPC, Ferdinando Borgese, VP, Commercial Director Intercontinental at Kedrion, and Chair of PPTA Europe, was among those who welcomed the opening ceremony, closed the first day and honored the 2023 Joachim Hilfenhaus Award.
Furthermore, Andrea Caricasole, Head of Research and Innovation at Kedrion, was also a speaker in the session entitled “The untapped potential of plasma and plasma-derived therapies – Past, current, and future outlook”.
Paolo Marcucci, Chairman of Kedrion, introduced the IPPC’s opening dinner, held on June 20, supported by Kedrion. He opened his speech by remembering that Kedrion has been a global member of the Plasma Protein Therapeutics Association and has been working alongside the Association since its foundation.
Paolo Marcucci introduced Ugo Di Francesco, CEO of Kedrion, who in turn gave a presentation describing Kedrion’s future and objectives, and underlying the company’s commitment to continue working to guarantee that an ever-increasing number of patients have access to the plasma-derived therapies they need.